We are thrilled to announce that this week, our esteemed partner Lion TCR has achieved IND approval from China’s NMPA for its groundbreaking mRNA TCR-T cell therapy (GZL-016), aimed at combating Hepatitis B virus-related hepatocellular carcinoma.
As Lion TCR’s trusted CDMO partner, Porton Advanced has delivered comprehensive CMC services, ensuring the highest quality deliverables and efficiency in bringing this innovative therapy to the forefront.
GZL-016 stands out as the first-in-class TCR-T cell therapy targeting the hepatitis B virus surface antigen, offering a promising treatment for patients with hepatitis B-related hepatocellular carcinoma.
Porton Advanced is proud to have supported our clients in securing 16 global IND approvals, including 4 from the FDA. We are currently engaged in 4 ongoing Phase I/II projects, underscoring our commitment to advancing cutting-edge therapies.
If you’re interested in conducting investigator-initiated Trial (IIT), IND, Phase I, II, BLA/NDA, or clinical trials, please reach out to us at info@portonadvanced.com.
